NanoViricides Announces First Patients Enrolled In Phase 2 Trial Of NV-387 For Mpox In Democratic Republic Of Congo
Share
Why It Matters
NanoViricides started testing a new mpox medicine on real patients. Watch if the company shares good or bad results from this test.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.